Cargando…

Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system

OBJECTIVE: To evaluate the accuracy and validity of an automated diabetic retinopathy (DR) screening tool (DART, TeleDx, Santiago, Chile) that uses artificial intelligence to analyze ocular fundus photographs for potential implementation in the national Chilean DR screening programme. METHOD: This w...

Descripción completa

Detalles Bibliográficos
Autores principales: Arenas-Cavalli, José Tomás, Abarca, Ignacio, Rojas-Contreras, Maximiliano, Bernuy, Fernando, Donoso, Rodrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727616/
https://www.ncbi.nlm.nih.gov/pubmed/33432168
http://dx.doi.org/10.1038/s41433-020-01366-0
_version_ 1784626561525219328
author Arenas-Cavalli, José Tomás
Abarca, Ignacio
Rojas-Contreras, Maximiliano
Bernuy, Fernando
Donoso, Rodrigo
author_facet Arenas-Cavalli, José Tomás
Abarca, Ignacio
Rojas-Contreras, Maximiliano
Bernuy, Fernando
Donoso, Rodrigo
author_sort Arenas-Cavalli, José Tomás
collection PubMed
description OBJECTIVE: To evaluate the accuracy and validity of an automated diabetic retinopathy (DR) screening tool (DART, TeleDx, Santiago, Chile) that uses artificial intelligence to analyze ocular fundus photographs for potential implementation in the national Chilean DR screening programme. METHOD: This was an observational study of 1123 diabetic eye exams using a validation protocol designed by the commission of the Chilean Ministry of Health personnel and retina specialists. RESULTS: Receiver operating characteristic (ROC) analysis indicated a sensitivity of 94.6% (95% CI: 90.9–96.9%), specificity of 74.3% (95% CI: 73.3–75%), and negative predictive value of 98.1% (95% CI: 96.8–98.9%) for the automated tool at the optimal operating point for DR screening. The area under the ROC curve was 0.915. CONCLUSIONS: The results of this study suggest that DART is a valid tool that could be implemented in a heterogeneous health network such as the Chilean system.
format Online
Article
Text
id pubmed-8727616
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87276162022-01-18 Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system Arenas-Cavalli, José Tomás Abarca, Ignacio Rojas-Contreras, Maximiliano Bernuy, Fernando Donoso, Rodrigo Eye (Lond) Article OBJECTIVE: To evaluate the accuracy and validity of an automated diabetic retinopathy (DR) screening tool (DART, TeleDx, Santiago, Chile) that uses artificial intelligence to analyze ocular fundus photographs for potential implementation in the national Chilean DR screening programme. METHOD: This was an observational study of 1123 diabetic eye exams using a validation protocol designed by the commission of the Chilean Ministry of Health personnel and retina specialists. RESULTS: Receiver operating characteristic (ROC) analysis indicated a sensitivity of 94.6% (95% CI: 90.9–96.9%), specificity of 74.3% (95% CI: 73.3–75%), and negative predictive value of 98.1% (95% CI: 96.8–98.9%) for the automated tool at the optimal operating point for DR screening. The area under the ROC curve was 0.915. CONCLUSIONS: The results of this study suggest that DART is a valid tool that could be implemented in a heterogeneous health network such as the Chilean system. Nature Publishing Group UK 2021-01-11 2022-01 /pmc/articles/PMC8727616/ /pubmed/33432168 http://dx.doi.org/10.1038/s41433-020-01366-0 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Arenas-Cavalli, José Tomás
Abarca, Ignacio
Rojas-Contreras, Maximiliano
Bernuy, Fernando
Donoso, Rodrigo
Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system
title Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system
title_full Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system
title_fullStr Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system
title_full_unstemmed Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system
title_short Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system
title_sort clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727616/
https://www.ncbi.nlm.nih.gov/pubmed/33432168
http://dx.doi.org/10.1038/s41433-020-01366-0
work_keys_str_mv AT arenascavallijosetomas clinicalvalidationofanartificialintelligencebaseddiabeticretinopathyscreeningtoolforanationalhealthsystem
AT abarcaignacio clinicalvalidationofanartificialintelligencebaseddiabeticretinopathyscreeningtoolforanationalhealthsystem
AT rojascontrerasmaximiliano clinicalvalidationofanartificialintelligencebaseddiabeticretinopathyscreeningtoolforanationalhealthsystem
AT bernuyfernando clinicalvalidationofanartificialintelligencebaseddiabeticretinopathyscreeningtoolforanationalhealthsystem
AT donosorodrigo clinicalvalidationofanartificialintelligencebaseddiabeticretinopathyscreeningtoolforanationalhealthsystem